Pyxis Oncology Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Pyxis OncologyDer Gewinn des Unternehmens wird voraussichtlich um 24.1% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 19.7% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich um 2% pro Jahr wachsen.

Wichtige Informationen

-24.1%

Wachstumsrate der Gewinne

2.0%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.2%
Wachstumsrate der Einnahmen	19.7%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	16 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Pyxis Oncology: Promising Research Amid Cash Constraints

Jun 10

Pyxis Oncology: Data Arriving Later Than Expected, But May Be Worth The Wait

Mar 28

Pyxis Oncology: Making A Bold Acquisition Move, But It's Not A Convincing Thesis

Jan 18

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:PYXS - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	6	-114	N/A	-107	4
12/31/2025	N/A	-87	N/A	-59	5
12/31/2024	13	-59	N/A	-63	5
3/31/2024	16	-58	-67	-65	N/A
12/31/2023	N/A	-74	-77	-71	N/A
9/30/2023	N/A	-94	-81	-73	N/A
6/30/2023	N/A	-99	-89	-76	N/A
3/31/2023	N/A	-109	-99	-88	N/A
12/31/2022	N/A	-121	-96	-89	N/A
9/30/2022	N/A	-101	-89	-84	N/A
6/30/2022	N/A	-88	-71	-71	N/A
3/31/2022	N/A	-71	-45	-44	N/A
12/31/2021	N/A	-76	-36	-35	N/A
9/30/2021	N/A	-64	-27	-26	N/A
6/30/2021	N/A	-53	-22	-22	N/A
3/31/2021	N/A	-47	-28	-27	N/A
12/31/2020	N/A	-13	-12	-10	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: PYXS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: PYXS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: PYXS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: PYXSDie Einnahmen des Unternehmens (19.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: PYXSDie Einnahmen des Unternehmens (19.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von PYXS in 3 Jahren voraussichtlich hoch sein wird

Pyxis Oncology Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates increase by 258%, EPS downgraded

Price target increased by 11% to US$8.00

Price target decreased by 40% to US$6.00

Price target decreased by 19% to US$8.67

Price target decreased by 19% to US$8.67

Price target decreased to US$11.00

Recent updates

Pyxis Oncology, Inc. Appoints Michael A. Metzger to Its Board of Directors

Pyxis Oncology: Promising Research Amid Cash Constraints

Consensus revenue estimates increase by 258%, EPS downgraded

Pyxis Oncology, Inc. Appoints Stephen Worsley as its Senior Vice President

Price target increased by 11% to US$8.00

Pyxis Oncology, Inc., Annual General Meeting, Jun 11, 2024

Pyxis Oncology: Data Arriving Later Than Expected, But May Be Worth The Wait

New major risk - Shareholder dilution

Pyxis Oncology, Inc. Appoints Santhosh Palani to Its Board of Directors

Pyxis Oncology, Inc. announced that it expects to receive $49.999989 million in funding from Blue Owl Healthcare Opportunities, StemPoint Capital LP, Deep Track Capital, LP, Laurion Capital Management LP, Ridgeback Capital Management LLC and another investors

Pyxis Oncology: Making A Bold Acquisition Move, But It's Not A Convincing Thesis

Pyxis Oncology, Inc. Appoints Ken Kobayashi, M.D., F.A.C.P, as Chief Medical Officer

Price target decreased by 40% to US$6.00

CEO, President & Director recently sold US$63k worth of stock

Pyxis Oncology, Inc. (NasdaqGS:PYXS) completed the acquisition of Apexigen, Inc. (NasdaqCM:APGN) from entities associated with Pfizer Inc. (NYSE:PFE), Lincoln Park Capital, LLC, managed by Laurion Capital Management LP, Bayer World Investments B.V. and others.

Price target decreased by 19% to US$8.67

High number of new and inexperienced directors

Price target decreased by 19% to US$8.67

Chief Medical Officer notifies of intention to sell stock

New minor risk - Market cap size

Pyxis Oncology, Inc. Advances Pyx-106 and PYX-201 Clinical Programs

Pyxis Oncology, Inc. (NasdaqGS:PYXS) entered into a definitive agreement to acquire Apexigen, Inc. (NasdaqCM:APGN) for $15.9 million.

Pyxis Oncology, Inc. (NasdaqGS : PYXS) entered into a definitive agreement to acquire Apexigen, Inc. (NasdaqCM : APGN) for $15.9 million.

Will Pyxis Oncology (NASDAQ:PYXS) Spend Its Cash Wisely?

Price target decreased to US$11.00

High number of new and inexperienced directors

Here's Why We're Watching Pyxis Oncology's (NASDAQ:PYXS) Cash Burn Situation

Pyxis Oncology, Inc. Appoints Rachel Humphrey to Its Board of Directors

Pyxis Oncology GAAP EPS of -$0.79 beats by $0.06

Pyxis Oncology, Inc. Appoints Jitendra Wadhane as Chief Accounting Officer and Principal Accounting Office

Pyxis Oncology, Inc.(NasdaqGS:PYXS) dropped from Russell 2500 Value Index

High number of new and inexperienced directors

High number of new and inexperienced directors

Pyxis Oncology Announces Leadership Changes

We're Hopeful That Pyxis Oncology (NASDAQ:PYXS) Will Use Its Cash Wisely

High number of new and inexperienced directors

Independent Director recently bought US$94k worth of stock

Independent Director recently bought US$200k worth of stock

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken